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• Define objective criteria for switch eligibility • Define switch treatment (drugs, doses) but allow flexibility for emerging therapies • State intent to statistically adjust for switch and likely primary and supportive methods to justify additional data collection, but allow flexibility to adapt methods to data pattern
What if full data collection is not practical?
This may happen if the decision to adjust for switch is post-hoc, or (for IPCW covariates) if post-progression survival is very long.
Review of NICE TAs with switch adjustment
Search methods and further details of results are available on request. 16 analysis groups [ITT analyses with associated switch adjusted analysis hazard ratios (HRs) and confidence intervals (CIs)] from 9 technology appraisals (TAs) involving 10 trials in advanced or metastatic cancer were identified 3,4 ( Table 2) . Trial sizes ranged from 162-750 patients, with switch rates (control to experimental) of 7%-84%.
• Impute missing data but be clear about assumptions -adds uncertainty •Simulate impact of missing data methods •Avoid anti-conservative methods • Use switch methods less affected by missing data if assumptions reasonable (e.g. RPSFTM)
• Post-progression, collect a few key covariates at less regular intervals than the ideal -preferable to no data due to patient over-burden and dropout Treatment switching occurs in a clinical trial when control arm patients switch to experimental therapy during the study. This often happens in oncology trials where patients switch following disease progression, and can reduce the observed survival difference. An estimate of the survival effect without switching may be required for economic modelling, and several methods have been developed to estimate this. In 2014, the NICE Decision Support Unit published Technical Support Document (TSD) 16 1 to provide guidance on this.
There are several practical considerations for the statistician or analyst wanting to apply these methods to clinical trials data 2 . The analysis framework proposed in TSD16 is useful, but it can be difficult to apply retrospectively unless the trial was designed with this objective in mind. So are there any trial design features that should be included in the protocol at the start? The right data must be collected to enable the methods to be applied -what data is that, is it practical to collect it all, what should be done if not? Each method has strong underlying assumptions such as a constant treatment effect or no unmeasured confounders -how could those assumptions be assessed for viability? Several recent health technology assessments have tried to apply these methods and shown either very different results from different models, or have struggled to fit the models at all. Why might that be? What could the analyst do in this situation?
Guidance will be provided on these issues based on experience of applying these methods to real-life data and a review of recent health technology assessments.
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